Weiss Asset Management LP Incyte Corp Transaction History

Weiss Asset Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$52.16 - $64.19 $404,083 - $497,279	7,747 New	7,747 $486,000
Q3 2021 Nov 12, 2021	SELL	$68.67 - $84.02 $494,355 - $604,859	-7,199 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$79.87 - $87.53 $574,984 - $630,128	7,199 New	7,199 $606,000
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $599,566 - $716,815	-10,249 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $483,330 - $602,355	5,166 Added 101.63%	10,249 $971,000
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $554,809 - $702,826	5,083	5,083 $593,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Weiss Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Weiss Asset Management LP with notifications on news.